The projected top performers are:
1. Actavis, a pharmaceutical company which successfully implemented the tax inversion strategy.
2. Perrigo Company Public Limited, a specialty pharmaceutical company in the process of tax inversion.
3. Merck & Co., a company in the major pharma sector.
4. Celgene, a biotech company focused on new therapies requiring collaboration.
5. Karyopharm Therapeutics, a small-mid-cap biotech company focused on cancer treatment in addition to other major diseases.
6. Thermo Fisher Scientific, which serves scientific endeavors.
7. Medtronic, a medical device company with a focus on orthopedics, which is also pursuing a tax inversion strategy.
8. Cigna, a healthcare insurance company expected to “face the least headwinds” when compared to peers.
More articles on healthcare:
Siouxland Surgery Center
ASC stock report—5 key company updates
32 ASC acquisitions in 2014
